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Background
Chemical compounds directly targeting epigenetic processes have emerged as poten-
tial treatments for metastatic disease (Fardi et al. 2018). Epigenetics involves alterations 
to the DNA and chromatin landscape and consequently gene expression patterns and 
biological processes (Dupont et al. 2009). The molecular alterations to the nucleosome-
forming histone proteins are one of the major epigenetic modifications that have been 
found to be altered in cancer (Audia and Campbell 2016). Compounds targeting these 
modifications, reverting them to a non-cancer state, have great therapeutic poten-
tial. Suberoylanilide Hydroxamic Acid (SAHA, commercially known as Vorinostat) 
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is approved by the FDA for the treatment of malignant cutaneous T-cell lymphoma 
(CTCL) (Kawamata et al. 2007). Subsequently, it was found to offer therapeutic potential 
for other cancer types including cervical and breast (Prestegui-Martel et  al. 2016; Shi 
et al. 2017) where female breast cancer represents around 30% of all new cancer cases 
in the US yearly, while uterine and cervical cancer make up to 7% of the total (Siegel 
et al. 2020). The use of MCF-7 and HeLa for breast and cervical cancer studies involving 
epigenetic drugs is well established due to the high genetic variability of these cells lines 
that could be tackled by such an approach (Landry et al. 2013; Zhou et al. 2019).
SAHA is a histone deacetylase (HDAC) inhibitor that can mediate the down-regu-
lation of DNA transcription in numerous biological processes (Haberland et  al. 2009) 
including cell growth arrest, activation of the extrinsic and intrinsic apoptotic pathways, 
autophagic, reactive oxygen species (ROS)-induced cell death, and mitotic cell death (Xu 
et  al. 2007; Ververis et  al. 2013; Zhang and Zhong 2014). Limitations in SAHA utility 
include low bioavailability, short half-life, and toxic side-effects, which are partly linked 
to the development of multidrug resistance (Bravo-Cordero et al. 2012; Friedl et al. 2012; 
Chung et al. 2013). Together, these factors have limited the clinical use of SAHA as an 
effective anti-cancer treatment (Konsoula and Jung 2008; Qi et al. 2017). Encapsulating 
SAHA within nanoparticles represents a potential strategy for overcoming such limita-
tions to enhance its utility in clinic.
Nanoparticles including liposomes (Lee 2020), bio-nanocapsules (Tsutsui et al. 2007), 
and polymeric nanoparticles (El-Say and El-Sawy 2017) are being developed to over-
come poor solubility and drug efficacy (Zhu and Liao 2015). Due to the unique physi-
ological and pathological features of the tumor site, correctly sized nanomicelles can be 
passively targeted due to the enhanced permeability and retention (EPR) effect, which 
can improve the drug efficacy and reduce toxic side-effects (Fang et al. 2011; Zhu et al. 
2016; Russo et al. 2016). Nanomicelles possess unique advantages including structural 
stability and simplicity of fabrication in a 10–100 nm size range (Tran et al. 2014; Kwak 
et  al. 2015). They can also effectively prolong the retention time of drugs in  vivo and 
prevent drug inactivation by enzyme degradation before reaching the tumor site (Biswas 
et al. 2013).
Pluronic is a water-soluble amphiphilic molecule with a poly(oxyethylene)-block-poly 
(oxypropylene)-block-poly(oxyethylene) (PEOx–PPOy–PEOz) triblock structure (Farru-
gia et al. 2014), which self-assembles forming core–shell micelles in aqueous media. For 
instance, chlorpromazine (CPZ)-containing Pluronic nanomicelles have been shown to 
enhance the cytotoxicity of the drug and increase its selectivity towards chronic myeloid 
leukemia cells, demonstrating the pharmacological potential for cancer treatment (Mello 
et al. 2016). Moreover, Solasodine, a type of steroidal alkaloid that exhibits excellent bio-
activities against fungi, viruses, and especially tumors, has been encapsulated into Plu-
ronic F127 nanocarriers, and was able to enhance the anti-cancer effect of Solasodine 
alone in A549 and Hela cells (Zhang et al. 2015). A similar approach has also been used 
for doxorubicin hydrochloride-loaded pluronic F127 nanocapsules which demonstrated 
delayed drug release (Zeng et al. 2014).
Here, we showed that the HDAC inhibitor SAHA can be efficiently loaded into plu-
ronic F127 nanomicelles. We demonstrate that SAHA-loaded nanomicelles are able to 
efficiently release the drug in a time-dependent fashion. SAHA nanomicelles were shown 
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to be more efficient than the free drug in reducing cell viability and inhibiting cell migra-
tion capacities of breast and cervical cancer cell lines, which represent two cancer types 
that still require more effective, epigenetic-based, treatments. Cellular uptake studies 
demonstrated the effective micellular uptake and intracellular distribution in a cell line-
dependent fashion. In addition, the encapsulated SAHA remained effective in trigger-
ing cell cycle arrest and apoptosis in a dosage-dependent manner. The HDAC inhibitor 
also altered the expression of the EMT markers E-cadherin and N-cadherin, suggesting 
that effective delivery has the potential to reverse the aggressive, metastatic phenotype 
of these cancer models.
Methods
Chemicals and reagents
Pluronic F127 was purchased from Sigma, China. SAHA was purchased from Nanjing 
Duolun Chemical Co., Ltd., China. Propidium Iodide (PI) was purchased from Santa 
Cruz Biotechnology. Acetonitrile, Dimethyl Sulfoxide (DMSO), Ammonium Persul-
fate, Sodium Chloride, Dodecyl Sodium Sulfate, Tween 20, Methanol, Ethanol, Isopro-
panol, and Chloroform were purchased from Sinopharm Chemical Reagent Co., Ltd., 
China. Phosphate-Buffered Saline, Dulbecco’s Modified Eagle Medium (DMEM), 1640 
Medium, Trypsin were purchased from Solarbio. Fetal Bovine Serum was purchased 
from Corning. MTT, Glycine, Tris(hydroxymethyl)aminomethane, and Acrylamide were 
purchased from Aladdin, China.
Preparation of SAHA–pluronic F127 nanoparticles
200 mg of Pluronic F127 and 3 mg of SAHA were dissolved into 10 ml of acetonitrile. 
Subsequently, the solvent was removed by rotary evaporation at 55℃ with decompres-
sion. The solid copolymer matrix obtained was then preheated at 65℃ for 1 h and even-
tually hydrated with phosphate buffer solution (PBS, 10 mM or 150 mM NaCl) or  H2O. 
The nanomicellar solution was filtered with a 0.22 μm filter to remove any free drug. PI 
encapsulation was similarly achieved. 10 mg PI and 200 mg were dissolved in 10 ml of 
acetonitrile, and followed the same process explained above. The dispersion, size, and 
zeta potential of nanomicelles were measured by dynamic light scattering (Particle size 
analyzer, Malvern, UK).
Atomic force microscope (AFM) characterization
10 μL of nanomicelle aliquots were spotted on mica substrates at a concentration of 
100  μg/mL (Agar Scientific, UK) and dried at room temperature. Sample topography 
was obtained in air using a Bruker BioScope Catalyst (Bruker Instruments, Santa Bar-
bara, California, USA) AFM. Bruker ScanAsyst-Air cantilevers were used, with a nomi-
nal spring constant of 0.4 N/m and a nominal resonant frequency of 70 kHz. All imaging 
was conducted using Peak Force Tapping (PFT) in ScanAsyst Mode. Images were pro-
cessed with first-order flattening and planefit using Bruker Nanoscope Analysis 1.5. 
Gwyddion in-built grain analysis was used to identify nanomicelles and to calculate their 
size.
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Nanomicelle stability
Nanoparticles were resuspended in either  H2O, PBS (10 mM NaCl), or PBS (150 mM 
NaCl), and stored at 4℃. To assess the stability of each formulation over time, size and 
poly-dispersion (PDI) measurements were taken at 0, 5, 10, 15, 20, 25, and 30 days.
Drug release assessment
A high-performance liquid chromatography (HPLC) system (Waters 2535, Milford, 
MA, US) equipped with a photodiode array detector was used for the analysis of 
the drug release potential of the pluronic formulations. A C18 HPLC column (Grac-
eSmart RP C18, 4.6 mm × 250 mm, 5 μm) was used for quantitative analysis of SAHA. 
Mobile phase A contained HPLC grade  H2O, and mobile phase B contained HPLC 
grade acetonitrile. SAHA was eluted with 50% mobile phase A and mobile phase B at 
a flow rate of 1 ml/min, with a retention time of 3.6 min and UV detection at 265 nm. 
Standard curves of concentration peaks and areas were drawn. Five-point calibration 
curves for SAHA in the range of 31.25–500 μM were considered reliable (r2 ≥ 0.999).
Determination of drug loading and entrapment efficiency.
200 μl of nanomicelle solution were added with 800 μl acetonitrile and centrifuged for 
5 min at 10,225×g. The supernatant was used to determine the concentration of drug 
by HPLC.
The entrapment efficiency (EE) and drug loading efficiency (DL) were calculated as 
follows:
In vitro drug release
To measure the release of SAHA from nanomicelles, a 20  ml solution containing 
SAHA-loaded nanomicelles was loaded into a dialysis bag (MWCO: 8000 ~ 14,000 Da, 
Spectrum®, Rancho Dominquez, CA, USA), which was immersed in 500 ml of 10 mM 
PBS (pH 7.4). Temperature was maintained at 37 °C. At predetermined time intervals, 
1 mL of release medium (PBS) was withdrawn and replaced with the same volume of 
fresh PBS into the system. The concentration of SAHA inside the solution was deter-
mined by HPLC.
Cell lines
HeLa (human epithelial cervical cancer) and MCF-7 (human breast adenocarcinoma) 
cell lines were kindly donated by Suzhou Institute of Nano-Tech and Nano-Bionics 
(SINANO), Chinese Academy of Sciences. HeLa cells were grown in DMEM and 
MCF-7 cells in RMPI. All media was supplemented with penicillin (100 U/ml) and 
DL% =
Weight of drug in nanomicelles
Weight of drug loaded nanomicelles
∗ 100%
EE% =
Weight of drug in nanomicelles
Weight of drug added into nanomicelles
∗ 100%.
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streptomycin (100 μg/ml) and 10% FBS at 37℃ in a humidified 5%  CO2 and 95% air 
atmosphere.
Cell proliferation assay
The anti-proliferative effects of SAHA, SAHA-loaded nanomicelles, and empty 
nanomicelles were assessed using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-
tetrazolium bromide (MTT) assay (Aladdin, China). 1 × 104cells/well were seeded 
in 96-well plates, grown overnight, and then treated with various concentrations of 
SAHA, SAHA-loaded nanomicelles, and empty nanomicelles for 24 h, 48 h, or 72 h. 
20 μL of MTT reagent were added to each well and left incubating for 4 h. The opti-
cal density was determined at 490  nm using a Multifunctional Microplate Reader 
(Thermo Fisher, China).
Protein blot
2.5 × 105 cells were dispersed in three 6-well plates, grown overnight, and three plates 
treated with SAHA, SAHA nanomicelles and empty nanomicelles for 24 h or 48 h. The 
cells were lysed in RIPA lysis buffer containing protease and phosphatase inhibitors 
(Beyotime, China) and total protein was estimated with BCA Protein Assay Kit (Beyo-
time, China). Protein was separated by SDS-PAGE and transferred on PVDF membranes 
(Beyotime, China). The membranes were blocked in 5% skimmed milk, incubated with 
primary antibodies for p21, p53, N-Cadherin or E-cadherin (Santac Cruz, US), and then 
incubated with the appropriate HRP conjugated secondary antibody (Absin, China).
Quantitative RT‑PCR (qRT‑PCR)
Hela and MCF-7 cells were treated with the SAHA and SAHA-loaded nanomicelles 
for 24 h or 48 h. Total RNA was isolated using the RNAiso Plus kit (Takara, Japan). 10 
μg of total RNA was converted into complementary DNA (cDNA) with PrimeScript 
RT reagent kit with gDNA Eraser (Takara, Japan). SYBR Premix Ex TaqTMII (Takara, 
Japan) solution was used according to the manufacturer’s protocol to measure for 
mRNA expression of p53, p21, E-cadherin and N-cadherin with by qPCR. GAPDH 
was used as a control to determine relative mRNA expression. The table below shows 




5′‑GCA CCG TCA AGG CTG AGA AC‑3′
5′‑TGG TGA AGA CGC CAG TGG A‑3′
p21 Forward primer
Reverse primer
5′‑GAT GGA ACT TCG ACT TTG TCACC‑3′
5′‑CTG CCT CCT CCC AAC TCA TC‑3′
p53 Forward primer
Reverse primer
5′‑ACT CCC CTG CCC TCA ACA A‑3′
5′‑ATC CAA ATA CTC CAC ACG CAAA‑3′
E‑cadherin Forward primer
Reverse primer
5′‑AGG ATG ACA CCC GGG ACA AC‑3′
5′‑TGC AGC TGG CTC AAG TCA AAG‑3′
N‑cadherin Forward primer
Reverse primer
5′‑CGA ATG GAT GAA AGA CCC ATCC‑3′
5′‑GCC ACT GCC TTC ATA GTC AAA CAC T‑3′
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Cellular uptake of nanomicelles
1.5 × 104 HeLa and MCF-7 cells/well were seeded in 8-well chambered coverslips (Ibidi). 
After 24 h from seeding, cells were treated with 1 µM of PI-loaded pluronic F127 nan-
oparticles and incubated at 37  °C in a humidified atmosphere. PBS was added as the 
untreated control. After 4 h, 24 h, and 48 h, cells were washed with 1X PBS and nuclei 
were counterstained with Hoechst 33342 (Life Technologies). 0.1% Triton-X-100 was 
used as a positive control and added to cells for 10 min to permeabilize them, followed 
by 1  µM PI treatment for 10  min. Cells were imaged live on a Zeiss LSM710 fluores-
cent confocal microscope (Carl Zeiss Microscopy, Jena) at a 40X magnification using the 
543 nm and 405 nm laser lines.
Cell migration assay
MCF7 and HeLa cells were seeded at a 5 × 105 cells/well concentration in 6-well plates. 
When cells reached 90% confluence scratches were performed with a 200  µl sterile 
pipette tip and detached cells were washed in 1× PBS. Subsequently, empty nanomi-
celles, SAHA nanomicelles, and free SAHA were added to each well, and the final vol-
ume was brought to 2 ml with FBS-free media. Images were acquired at 0 h, 24 h, and 
48 h using a Zeiss inverted microscope at a 4× magnification.
Reference marks on the bottom of each well along the scratches were made to align the 
same fields in each image acquisition, at each time point. Image analysis of the scratches 
was performed using the Wound Healing Size Tool, an ImageJ/Fiji® plugin that allows for 
the quantification of the wounded area (Suarez-Arnedo et al. 2020). The scratch area was 
calculated for each field and time point, and the percentage of wound closure was calcu-
lated according to the following formula:
where At=0 is the area of a specific field at time 0 h and At=Δt is the area of the same 
field after n hours of the initial scratch. The data were graphed and analyzed using 
GraphPad Prism. For the statistical analysis, it was used one-way ANOVA with Dun-
nett’s multiple comparison test.
Statistical analysis
Data were expressed as mean ± standard deviation and analyzed using SPSS software. 
According to the distribution type of the data, the samples were processed by T test and 
one-way ANOVA analysis with Dunnett’s multiple comparison test. A p value p < 0.05 
was considered statistically significant.
Results
Characterization and assessment of stability of SAHA‑loaded nanomicelles over time
Nanomicelles were fabricated using a thin-film method and characterized by dynamic 
light scattering. Empty and SAHA-loaded nanomicelles both had an average size of 
23 nm and a poly-dispersive index (PDI) of 0.09 ± 0.02 and 0.08 ± 0.0, respectively, con-
firming the uniformity of distribution of the formulation (Table 1). The surface charge of 
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a zeta-potential value of −  1.28 ± 0.28 mV. The entrapment efficiency (EE%) and drug 
loading efficiency (DL%) values were 94.36 ± 0.76% and 1.31 ± 0.062%, respectively.
Particles were imaged using Atomic Force Microscope (AFM) and identified using 
the grain analysis algorithm in Gwyddion (Kohn et  al. 2018). Nanomicelles showed a 
rounded shape and both empty (Fig. 1a) and SAHA-loaded (Fig. 1b) nanomicelles pre-
sented a diameter of 32 nm. Both AFM and DLS experiments confirmed that no change 
was detectable in micelles dimensions upon incorporation of the drug.
Table 1 Characterization of SAHA-encapsulated pluronic nanomicelles
Size, PDI, and surface charge were analyzed using Malvern’s Zetasizer Nano. Entrapment efficiency and drug loading 
efficiency were calculated as explained in Sect. 2.2
Size PDI Zeta potential EE% DL%
SAHA‑loaded pluronic F127 
nanomicelles
22.98 ± 1.01 0.08 ± 0.01 − 1.28 ± 0.28 94.36 ± 0.76 1.31 ± 0.06
Pluronic F127 nanomicelles 22.56 ± 0.3 0.09 ± 0.02
Fig. 1 AFM characterization. Empty nanomicelles and SAHA‑loaded nanomicelles are shown at the top 
of a and b, respectively. Z range: 0–1.8 nm. Gwyddion grain analysis was used to identify nanomicelles 
(bottom images, masking is highlighted in purple) and to calculate their diameter. Not all nanomicelles were 
considered for grain analysis due to low masking performance
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To determine nanomicelle stability, particle size was evaluated in three different 
solutions  (H2O, 10  mM PBS and 150  mM PBS) at different time points for up to 
30 days (Fig. 2). In all three solutions, the initial particle size of SAHA nanomicelles 
was 30  nm. In  H2O, the micelles aggregated over time, increasing six-fold in size 
compared to day 0 (Fig. 2a). Less aggregation was observed in 10 mM PBS (Fig. 2b), 
and no aggregation was observed for nanomicelles in PBS-containing physiological 
NaCl concentrations (150 mM, Fig. 2c). PBS (150 mM NaCl) was, therefore, selected 
for all further experiments.
Sustained release profiling
SAHA-loaded nanomicelles were analyzed for their capacity to sustain SAHA release 
over time (Fig.  3). SAHA was retained for a longer period of time when loaded in 
nanomicelles with only 36.53% ± 3.43 of drug released after 2  h and 85.68% ± 2.48 
after 72  h, compared to free SAHA where levels reached 51.55% ± 1.56 after 2  h, 
96.27% ± 3.47 after 72 h.
Fig. 2 Analysis of nanoparticles stability over time. The aggregation of nanomicelles in three different 
solvents was investigated at 0, 5, 10, 15, 20, 25, and 30 days. Nanoparticles were kept at 4℃. 1a  H2O; 1b 
10 mM PBS; 1c 150 mM PBS
Fig. 3 In vitro drug release of SAHA from nanomicelles. Nanomicelles encapsulated with SAHA and 
resuspended in PBS were tested for their capacity to release the drug over time. HPLC was used to measure 
the amount of SAHA released after up to 72 h. The ± SD value of the data was tested by T test (n = 3)
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Nanomicelles cellular uptake
To understand the mechanisms of nanomicelle uptake, HeLa and MCF-7 cells were 
exposed to F127 nanomicelles loaded with the fluorescent dye propidium iodide (PI). 
Cellular uptake was assessed at 4  h, 24  h and 48  h time points. Nanomicelle uptake 
by HeLa cells was measured by confocal microscopy at two different concentrations, 
0.1 μM and 1 μM (Fig. 4). Treatment with 0.1 μM nanomicelles yielded a noticeable PI 
uptake after 48 h, while the PI signal could already be visualized after 4 h following expo-
sure to 1 μM PI nanomicelles, where a clear co-localization signal was observed in the 
cell nuclei (blue, Fig. 4).
Treatment of MCF-7 cells with PI nanomicelles resulted in a different temporal cel-
lular uptake pattern compared to HeLa cells (Fig. 5). Treatment with 0.1 μM PI nanomi-
celles resulted in particle localization at the peri-nuclear zone after 24 h, and localization 
within the nuclei after 48 h, showing the intracellular transport of these particles to the 
nucleus can be accomplished using the delivery system. At higher treatment concen-
trations (1  μM), particles reached the cell nuclei after only 4  h from the addition and 
yielded the highest signal after 48 h.
SAHA‑loaded nanomicelles inhibit Hela cell and MCF‑7 cell proliferation
The ability of SAHA-loaded nanomicelles to inhibit cell proliferation in both Hela and 
MCF-7 cancer cell lines was assessed. HeLa and MCF7 cell lines were treated with 1 μM 
and 5 μM of free drug or SAHA-encapsulated nanoparticles for up to 72 h. The 1 μM 
Fig. 4 PI nanomicelle uptake by HeLa cells. Confocal images were taken at 4 h, 24 h, and 48 h after the 
treatment. A negative control with unstained cells and a positive control involving the addition of Triton‑X 
followed by PI were used. Cell nuclei are stained in blue, while PI fluorescent signal is highlighted in red
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concentration of free and encapsulated drug displayed similar toxicities with both Hela 
and MCF7 cells after 24 h and 48 h (Fig. 6a, c), while the nanomicelles became signifi-
cantly more effective than the free drug after 72 h on HeLa cells (p < 0.05). Conversely, 
the 5 μM concentration of SAHA-encapsulated nanomicelles proved to be more effec-
tive than the free drug after 48 h for both HeLa (p < 0.05, Fig. 6b) and MCF7 (p < 0.01, 
Fig.  6d). The same trends were maintained after 72  h of exposure to the treatment 
for both HeLa and MCF7 cells. These observations suggested that nanomicelle encapsu-
lation of SAHA serves to enhance its cytotoxicity.
Effect of SAHA‑loaded nanomicelles on cell cycle and EMT
To evaluate the effect of SAHA encapsulation on the expression of p21 and p53 (cell 
cycle markers) and E/N-cadherins (EMT markers), HeLa cells were treated with free 
and encapsulated drug for 24 h and 48 h. Increasing concentrations of both free drug 
and SAHA-encapsulated nanomicelles led to a significant up-regulation of p21 (p < 0.05) 
and a down-regulation of p53 (p < 0.05) at both 24 h (Fig. 7a, b) and 48 h (Fig. 7d–e). 
Moreover, SAHA-loaded nanomicelles were more effective than free SAHA (p < 0.05) in 
triggering alterations at the protein level (Figs. 7a, 4b), and this effect was corroborated 
by mRNA expression analysis of the same markers (Figs.  7c, 4f ), with SAHA-loaded 
nanomicelles having a significantly greater effect on the expression of p21 and p53 
mRNA (p < 0.01) than free drug. The effect of SAHA and SAHA-loaded nanomicelles on 
Fig. 5 Fig. 4 PI nanomicelles uptake by MCF‑7 cells. Confocal images of MCF‑7 cells were taken at 4 h, 24 h 
and 48 h after treatment. A negative control with unstained cells and a positive control involving the addition 
of Triton‑X followed by PI were used. Cell nuclei are stained in blue, while PI fluorescent signal is highlighted 
in red
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p21 and p53 protein expression appears concentration-dependent, with drug encapsula-
tion potentiating the effect of SAHA in nanomicelles.
The effect of SAHA encapsulation in metastatic processes was undertaken by deter-
mining the expression patterns of E-cadherin and N-cadherin. After 24  h, SAHA and 
SAHA-loaded nanomicelle treatement resulted in a significant up-regulation of E-cad-
herin protein in Hela cells (p < 0.05) (Fig. 7c). Similarly, the 48 h treatment with either 
SAHA and SAHA nanomicelles resulted in significantly increased E-cadherin expression 
(p < 0.05) (Fig. 7f ). SAHA-encapsulated nanoparticles were more effective than free drug 
in increasing E-cadherin levels. However, neither SAHA nor SAHA-loaded nanomicelles 
had an effect on N-cadherin expression.
The same analysis was performed on MCF-7 cells, which displayed a similar response 
to Hela cells after 24 h treatment, with both SAHA and SAHA-loaded micelles signifi-
cantly up-regulating p21 and down-regulating p53 protein (Fig. 8a) and mRNA expres-
sion levels (Fig.  8b). The same trend was seen after 48  h (Fig.  8d–e). Furthermore, 
SAHA-loaded nanomicelles exhibited a greater effect on protein expression on both tar-
gets compared to free SAHA (p < 0.05). Furthermore, gene expression analysis showed a 
significant increase in E-cadherin and decrease in N-cadherin after 24 h (Fig. 8c), which 
was maintained after 48 h for E-cadherin only (Fig. 8f ). In general, SAHA-encapsulated 
nanoparticles were more effective in increasing the levels of E-cadherins than the free 
drug.
Fig. 6 Anti‑proliferative effect of SAHA on Hela and MCF‑7 cells. a, b Effect of different drug concentrations 
on Hela cells at 24 h, 48 h, and 72 h. c, d effect of different drug concentrations on MCF‑7 cells at 24 h, 48 h, 
and 72 h. Survival rate was measured by MTT assay. The percentage of viable cells was determined as the 
ratio of treated cells to untreated controls. A one‑way ANOVA was used to test for statistical significance 
(*p < 0.05, **p < 0.01, ***p < 0.001)
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Fig. 7 Protein and mRNA expression of p21, p53, and E/N‑cadherins in Hela cells after 24 h (top) or 48 h 
(bottom). Cells were analyzed by western blot and qPCR. a, d Effect of SAHA and SAHA‑loaded nanomicelles 
on the protein expression of the four markers in Hela cells at 24 and 48 h. b, e mRNA analysis of p21 and p53 
markers on Hela cells at 24 and 48 h. c, f Effect of SAHA and SAHA‑loaded nanomicelles on E and N‑cadherin 
mRNA expression in Hela cells at both time points. Data were normalized to the level of GAPDH. Data were 
tested by T test for statistical significance (n = 3, *p < 0.05, **p < 0.01, ***p < 0.001)
Fig. 8 Protein and mRNA expression of p21 and p53 in MCF‑7 cells after 24 h (top) or 48 h (bottom). The 
effect of SAHA and SAHA‑loaded nanomicelles on p53 and p21 protein expression in MCF‑7 cells was 
analyzed. Expression of all four markers was analyzed by western blot at 24 h (a) and 48 h (d). Data were 
normalized to the level of GAPDH. The effect of SAHA and SAHA‑loaded nanomicelles on p21 and p53 mRNA 
expression was also done at 24 h (b) and 48 h (e), and normalized to the level of GAPDH, while the E‑ and 
N‑cadherin mRNA analysis at 24 h and 48 h is shown in (c) and (f), respectively. The expression level is shown 
relative to the control as 1. A t test to test for statistical significance was performed (*p < 0.05, **p < 0.01, 
***p < 0.001)
Page 13 of 17Pisano et al. Cancer Nano           (2020) 11:14  
Analysis of cell migration capacity following SAHA nanomicelle exposure
0.1 μM SAHA nanomicelles were assessed for their ability to inhibit HeLa and MCF-7 cell 
growth and migration using a wound-healing assay. Following treatment for 24 h and 48 h, 
a time-dependent effect of the treatment on HeLa cell division and inhibition of migration 
was observed (Fig.  9a). After 24  h, both SAHA nanomicelles and SAHA were found to 
inhibit wound closure compared to empty nanomicelles (p < 0.01 and p < 0.05 respectively, 
Fig. 9b). After an extended 48 h treatment period, the negative effect of SAHA nanomi-
celles on wound closure was more marked than the free drug, which surprisingly was even 
less effective than the empty nanomicelle treatment (p < 0.001, Fig. 9c).
Similarly, when MCF-7 cells were exposed to 0.1  μM SAHA nanomicelles, a clear 
decrease in wound-healing capacity was observed after 24  h (Fig.  10a, b). Moreover, 
this effect was more enhanced after 48 h, where SAHA-nanomicelles yielded the most 
marked reduction in wound closure (p < 0.001) compared to SAHA only (p < 0.05, 
Fig. 10c).
Discussion
Here, we have demonstrated that the histone deacetylase inhibitor SAHA can be effec-
tively encapsulated in pluronic nanoparticles. We confirmed, by means of dynamic light 
scattering and AFM analysis, that the size and phenotype of nanomicelles did not change 
upon SAHA encapsulation.
As SAHA has been shown to cause harmful side-effects, analysis of the amount of 
encapsulated drug within the nanomicelles was undertaken, as encapsulation could be 
an effective route to reducing systemic toxicity. Reported side-effects include fatigue, GI 
related diarrhea, nausea, thrombocytopenia, and anorexia as observed in different types 
of cancers, including endometrial cancers and lymphomas (Takai et  al. 2004; Duvic 
2008).
Fig. 9 Effect of SAHA‑loaded nanomicelles on the wound closure capacity of HeLa cells. Representative 
microscope images (Fig. 10a) and analysis (Fig. 10b) of the wound closure. Wound closure capacity values are 
shown relative to the empty nanomicelles control. A one‑way ANOVA with Dunnett’s multiple comparison 
test for statistical significance was performed (*p < 0.05, **p < 0.01, ***p < 0.001)
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Drug release experiments showed that SAHA was  progressively released from plu-
ronic nanomicelles for up to 72 h. These results were complemented by the analysis of 
the uptake of nanomicelles by breast and cervical cancer cell lines MCF-7 and HeLa, 
which showed a time-dependent nanomicelle uptake that was more enhanced in the 
MCF-7 cell line after 48 h. This effect could be due to different intracellular uptake pat-
terns of nano-encapsulated formulations by different cell types. Indeed, the majority of 
free drugs enter cells through a simple diffusion process, while most nanocarrier drugs 
enter cells through endocytosis (Kumari et  al. 2016; Behzadi et  al. 2017; Foroozandeh 
and Aziz 2018). These findings are in line with the previous reports that showed the effi-
cient employment of pluronic F127 for the encapsulation and cellular uptake of com-
pounds, such as curcumin (Wang et al. 2015; Vaidya et al. 2019), paclitaxel (Nie et al. 
2011), and doxorubicin (Manaspon et al. 2012).
Experiments showed that nanomicelle-encapsulated SAHA was more effective than 
the free drug in causing cell death. This effect was most evident after 72 h, suggesting 
a sustained release of SAHA over time. Encapsulation could, therefore, result in the use 
of less drug while still obtaining the required therapeutic effect, or in the more effec-
tive and tumor site specific delivery due to the inherent properties of nanostructures. A 
wound-healing assay further demonstrated the effectiveness of SAHA nanomicelles over 
longer time periods for HeLa and MCF-7 cells, with a slightly different effect observed 
with each cell line. Indeed, the fact that breast cancer cells were more susceptible to the 
effect of SAHA nanomicelles than cervical cancer cells might provide insights for future 
therapeutic approaches.
SAHA treatment caused significant changes in proteins involved in both cell cycle and 
cell phenotype. We demonstrated that SAHA-loaded nanomicelles were able to up-reg-
ulate p21 and down-regulate p53 expression, consistent with the previous studies on the 
action of free SAHA on tumor growth inhibition by regulating the expression of these 
genes (Davies et al. 2015; Ogata et al. 2017).
Fig. 10 Effect of SAHA‑loaded nanomicelles on the wound closure capacity of MCF7 cells. Representative 
microscope images (a) and analysis (b) of wound closure. Wound closure capacity values are shown relative 
to the empty nanomicelles control. A one‑way ANOVA with Dunnett’s multiple comparison test for statistical 
significance was performed (*p < 0.05, **p < 0.01, ***p < 0.001)
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Detailed analysis of the effects of SAHA-loaded nanoparticles on EMT transition 
markers revealed a significant up-regulated E-cadherin expression, but with no affect 
N-cadherin expression. This is consistent with previous studies, where HDAC inhibitors 
were shown to have only a slight effect on N-cadherin expression in HT-144 and A375 
cells (Díaz-Núñez et al. 2016). Down-regulation or loss of E-cadherin expression affects 
cadherin-catenin complex formation and stability, which directly affects the metastatic 
process (Zhang et  al. 2000; Guo et  al. 2018). It has been suggested that SAHA may 
inhibit the formation of Snail and HDAC1/HDAC2 complexes by inhibiting the activity 
of HDAC1 and HDAC2, leading to the demethylation and transcriptional activation of 
the E-cadherin. In addition, SAHA may also up-regulate E-cadherin expression by alter-
ing its upstream targets (LEF-1 and Slug) (Nalls et al. 2011), but the specific mechanisms 
need to be further elucidated.
Conclusions
Encapsulation of SAHA into nanomicelles enhances the potency of this epigenetic drug 
in breast and cervical cancer cell models. Furthermore, this effective formulation will 
likely enhance drug delivery to tumor sites, and overcome current issues in deliver-
ing HDAC  inhibitors to solid tumors, while also reducing side-effects associated with 
systemic delivery of the free drug. The EPR effect would enable these nanoparticles to 
escape via neo-vascularization at tumor sites, and subsequently, their physico-chemi-
cal characteristics would allow better penetration into solid tumors (Blanco et al. 2015; 
Zhang et  al. 2019). Such parameters are likely to be specific to different cancer types, 
and indeed, we observed that the SAHA-loaded nanomicelles displayed different uptake 
rates, and directed intracellular trafficking in the two different cancer cell models tested 
here (Figs. 4, 5).
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